Skip to content
Screener

Jade Biosciences JBIO Total Liabilities

Total Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.12B+11.6%
Climb Global Solutions, Inc. logo
Climb Global Solutions, Inc.CLMB
$340.41M+24.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$456.46M-11.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$122.04M+62.4%
Vor Biopharma logo
Vor BiopharmaVOR
$657.17M+1,420%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$42.12M+91.4%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.35B+436%
Enterprise value$1.3B+3,925%

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by Jade Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:27 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212088
Line itemMarch 31,2026December 31,2025
Total current liabilities22,29216,539
Long-term liabilities:
Long-term lease liability679724
Total liabilities22,97117,263
Commitments and contingencies (Note 12)
Stockholders’ equity:
Series A non-voting convertible preferred stock, $0.0001 par value; 12,622 shares authorized as of both March 31, 2026 and December 31, 2025; 12,622 shares issued and outstanding as of both March 31, 2026 and December 31, 202522
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 49,345,967 and 49,316,287 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively55

Item 1. Financial Statements.

FAQ

What is Jade Biosciences's total liabilities?
Jade Biosciences (JBIO) reported total liabilities of $22.97M in Q1 2026.
How has Jade Biosciences's total liabilities changed year-over-year?
Jade Biosciences's total liabilities increased by 823.6% year-over-year, from $2.49M to $22.97M.
What is the long-term trend for Jade Biosciences's total liabilities?
Over 5 years (2020 to 2025), Jade Biosciences's total liabilities has grown at a 57.6% compound annual growth rate (CAGR), from $1.77M to $17.26M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Jade Biosciences's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude